Chemotherapy/chemoradiation in anal cancer: A systematic review

Cancer Treatment Reviews

Volumn 37, Issue 7, 2011, Pages 520-532

  Lim, Faye ^a   Glynne Jones, Rob ^a  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

Anal cancer; Chemoradiation; Chemotherapy

Indexed keywords

ADRIAMYCINONE; BLEOMYCIN; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; ETOPOSIDE; FLUOROPYRIMIDINE; FLUOROURACIL; GEMCITABINE; METHOTREXATE; MITOMYCIN; MITOMYCIN C; NAVELBINE; OXALIPLATIN; PACLITAXEL; PLATINUM; SORAFENIB; TOPOTECAN; VINCRISTINE;

ANUS CANCER; ANUS DISEASE; ANUS FISTULA; ANUS ULCER; BASAL CELL CARCINOMA; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COLOSTOMY; CONTINUOUS INFUSION; DIARRHEA; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG MEGADOSE; FIBROSIS; FOLLOW UP; HEMATOLOGIC DISEASE; HUMAN; LEUKOPENIA; LOW DRUG DOSE; METASTASIS; MULTIPLE CYCLE TREATMENT; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RECTUM DISEASE; RECTUM STENOSIS; RETROSPECTIVE STUDY; REVIEW; SINGLE DRUG DOSE; SKIN ULCER; SQUAMOUS CELL CARCINOMA; SYSTEMATIC REVIEW; TREATMENT RESPONSE; UTERINE CERVIX CANCER;

ANTINEOPLASTIC AGENTS; ANUS NEOPLASMS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; RADIOTHERAPY;

EID: 80052353425     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2011.02.003     Document Type: Review

References (113)

1. Boman B.M., Moertel C.G., O'Connell M.J., Scott M., Weiland L.H., Beart R.W., et al. Carcinoma of the anal canal. A clinical and pathologic study of 188 cases. Cancer 1984, 54:114-125.
2. UKCCCR Anal Cancer Working Party. Epidermoid Anal Cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil and Mitomycin. Lancet 1996;348:1049-54.
3. Bilimoria K.Y., Bentrem D.J., Rock C.E., et al. Outcomes and prognostic factors for squamous-cell carcinoma of the anal canal: analysis of patients from the National Cancer Data Base. Dis Colon Rectum 2009, 52(4):624-631.
4. Nigro N.D., Vaitkevicius V.K., Considine B., et al. Combined therapy for cancer of the anal canal: a preliminary report. Dis Colon rectum 1974, 17:354-356.
5. Nigro N.D. An evaluation of combined therapy for squamous call carcinoma of the anal canal. Dis Colon Rectum 1984, 27:763-766.
6. Leichman L., Nigro N., Vaitkevicius V.K., et al. Cancer of the anal canal: model for preoperative adjuvant combined modality therapy. Am J Med 1985, 78(2):211-215.
7. Byfield J.E., Barone R.M., Sharp T.R., et al. Conservative management without alkylating agents of squamous cell anal cancer using cyclical 5FU alone and X-ray therapy. Cancer Treat Rep 1985, 67:709-712.
8. Cummings B.J., Keane T.J., O'Sullivan B., et al. Epidermoid anal cancer: treatment by radiation alone or by radiation and 5-fluorouracil with and without mitomycin. Int J Radiat Oncol Biol Phys 1991, 21(5):1115-1125.
9. Bartelink H., Roelofsen F., Eschwege F., et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European organization for research and treatment of cancer radiotherapy and gastrointestinal cooperative groups. J Clin Oncol 1997, 15:2040-2049.
10. Flam M., John M., Pajak T.F., et al. Role of mitomycin in combination with fluorouracil and radiotherapy and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol 1996, 14:2527-2539.
11. Ajani J.A., Winter K.A., Gunderson L.L., et al. Fluorouracil, mitomycin and radiotherapy vs fluorouracil, cisplatin and radiotherapy for carcinoma of the anal canal: a randomised controlled trial. JAMA 2008, 199:1914-1921.
12. Peiffert D., Gerard J.P., Ducreux M., et al. Induction chemotherapy (ict) and dose intensification of the radiation boost in locally advanced anal canal carcinoma (laacc): definitive analysis of the Intergroup Accord 03 trial (Fédération Nationale des centres de lutte contre le cancer) Fondation Française de Cancérologie Digestive. Radiother Oncol 2008, 88(Suppl. 2):S20. [abstract 65].
13. Conroy T., Ducreux M., Lemanski C. Treatment intensification by induction chemotherapy (ICT) and radiation dose escalation in locally advanced squamous cell anal canal carcinoma (LAAC): definitive analysis of the intergroup ACCORD-03 trial. J Clin Oncol 2009, 27(15s (Part I of II)):176s. [abstract 4033].
14. Ajani J.A., Winter K.A., Gunderson L.L., et al. US intergroup anal carcinoma trial: tumor diameter predicts for colostomy. J Clin Oncol 2009, 27(7):1116-1121.
15. James R., Wan S., Glynne-Jones R., et al. A randomised trial of chemoradiation using mitomycin or cisplatin, with or without maintenance cisplatin/5FU in squamous cell carcinoma of the anus. J Clin Oncol (Proc ASCO) 2009, 27(18S (part II of II)):797s. [abstract LBA-4009].
16. Pathak P, King BT, Ohinata A, et al. The treatment of metastatic squamous cell carcinoma of the anal canal: a single institution experience. In: ASCO GI Cancers Symposium; 2008 [abstract A352].
17. James RD, Cunningham D, Davidson N, et al. Chemoradiation and maintenance chemotherapy for patients with anal carcinoma: a phase II trial of the UK co-ordinating committee for cancer research (UKCCCR) anal cancer working party. J Clin Oncol 2000;19 [Proc. ASCO abstract 1045].
18. Glynne-Jones R., Meadows H., Wan S., et al. National cancer research institute anal subgroup and colorectal clinical oncology group. EXTRA - a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin in anal cancer. Int J Radiation Oncol Biol Phys 2008, 72(1):119-126.
19. Crehange G., Bosset M., Lorchel F., et al. Combining cisplatin and mitomycin with radiotherapy in anal carcinoma. Dis Colon Rectum 2006, 50:43-49.
20. Eng C., Chang G.J., Das P., et al. Phase II study of capecitabine and oxaliplatin with concurrent radiation therapy (XELOX-XRT) for squamous cell carcinoma of the anal canal. J Clin Oncol 2009, 27:15s. [abstract 4116].
21. Sischy B., Doggett R.L.S., Krall J.M., et al. Definitive irradiation and chemotherapy for radiosensitization in management of anal carcinoma: interim report on Radiation Therapy Oncology Group Study No. 8314. J Natl Cancer Inst 1989, 81:850-856.
22. John M., Pajak I., Flam M., et al. Dose escalation in chemoradiation for anal cancer: preliminary results of RTOG 9208. Cancer J Sci Am 1996, 2:2205.
23. Konski A., Garcia M., John M., et al. Evaluation of planned treatment breaks during radiation therapy for anal cancer: update of RTOG 92-08. Int J Radiat Oncol Biol Phys 2008, 72(1):114-118.
24. Vaz F, Trindade C, Barata A, et al. Sequential and concomitant chemoradiation (CTR) therapy with flurouracil (5FU) and cisplatin (CDDP) for anal squamous cell carcinoma (ASCC). J Clin Oncol 1998;17:304 [Proc. ASCO abstract 1173].
25. Peiffert D., Giovannini M., Ducreux M., et al. High-dose radiation therapy and neoadjuvant plus concomitant chemotherapy with 5-fluorouracil and cisplatin in patients with locally advanced squamous-cell anal carcinoma: final results of a phase II study. Ann Oncol 2001, 12:397-404.
26. Gerard J.P., Romestaing P., Mornex F., Ardiet J.M. Radiochemotherapy in anal carcinoma (ACC). A randomised trial comparing fluorouracil-cisplatin (5FU-CDDP) and CDDP alone. Eur J Cancer 1999, S143. [abstract 523].
27. Meropol N.J., Niedzwiecki D., Shank B., et al. Induction therapy for poor-prognosis anal canal carcinoma: a phase II study of the cancer and Leukemia Group B (CALGB 9281). J Clin Oncol 2008, 26(19):3229-3234.
28. Bosset J.F., Roelofsen F., Morgan D.A.L., et al. Shortened irradiation schedule, continuous infusion of 5-fluorouracil and fractionation of mitomycin in locally advanced anal carcinomas. Results of a phase II study of the European Organization for Research and Treatment of Cancer. Radiotherapy and Gastrointestinal Cooperative Groups. Eur J Cancer 2003, 39:45-51.
29. Martenson J.A., Lipsitz S.R., Leftkopoulou M., et al. Results of combined modality therapy for patients with anal cancer (E7283): an Eastern Cooperative Oncology Group study. Cancer 1995, 76(10):1731-1736.
30. Martenson J.A., Lipsitz S.R., Wagner H., et al. Initial results of a phase II trial of high dose radiation therapy, 5-fluorouracil, and cisplatin for patients with anal cancer (E4292). Int J Radiat Oncol Biol Phys 1996, 35:745-749.
31. Matthews John Early anal canal carcinoma - the Trans-Tasman Radiation Onocology Group (TROG) experience in TROG 99.02 study. Australas Radiol 2005, 49(2):A3. on behalf of TROG 99.02 participants.
32. Doci R., Zucali R., La Monica G., Meroni E., Kenda R., Eboli M., et al. Primary chemoradiation therapy with fluorouracil and cisplatin for cancer of the anus: results in 35 consecutive patients. J Clin Oncol 1996, 14:3121-3125.
33. Olivatto L.O., Meton F., Bezerra M., et al. Phase I study of cetuximab (CET) in combination with 5-flurouracil (5FU), cisplatin (CP) and radiotherapy (RT) in patients with locally advanced squamous cell anal carcinoma (LAAC). J Clin Oncol 2008, 26(15S):240. [abstract 4609].
34. Olivatto L.O., Cabral V., Rosa A., et al. Mitomycin-C or cisplatin-based chemoradiotherapy for anal canal carcinoma: long-term results. Int J Radiat Oncol Biol Phys 2011, 79(2):490-495.
35. Matzinger O., Roelofsen F., Mineur L., et al. For the EORTC Radiation Oncology and Gastrointestinal Tract Cancer Groups. Mitomycin with continuous fluorouracil or with cisplatin in combination with radiotherapy for locally advanced anal cancer (European Organisation for Research and Treatment of Cancer phase II study 22011-40014). Eur J Cancer 2009, [Epub ahead of print].
36. Northover J., Glynne-Jones R., Sebag-Montefiore D., et al. Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I). Br J Cancer 2010, 102(7):1123-1128.
37. John M., Flam M., Berkley B., et al. Five year results and analyses of a phase III randomised RTOG/ECOG chemoradiation protocol for anal cancer. J Clin Oncol 1998, 17:258a. [abstract 989].
38. Peiffert D., Gerard J.P., Ducreux M., et al. Induction chemotherapy (ICT) and dose intensification of the radiation boost in locally advanced anal cancer (LAACC): interim analysis of the 101 first randomised patients (pts) in the Intergroup ACCORD 03 trial (Federation Nacionale des Centres de Lutte Contre le Cancer - Fondation Francaise de Cancerologie Digestive). Eur J Cancer 2005, (Suppl. 3/2):172. [abstract 61].
39. Tournier-Rangeard L., Mercier M., Peiffert D., et al. Radiochemotherapy of locally advanced anal canal carcinoma: prospective assessment of early impact on the quality of life (randomised trial ACCOR 03). Radiother Oncol 2008, 87(3):391-397.
40. Wilking N., Petrelli N., Herrera L., Mittelman A. Phase II study of combination bleomycin, vincristine and high-dose methotrexate (BOM) with leucovorin rescue in advanced squamous cell carcinoma of the anal canal. Cancer Chemother Pharmacol 1985, 15(3):300-302.
41. Hainsworth J.D., Burris H.A., Meluch A.A., et al. Paclitaxel, carboplatin and long-term continuous infusion of 5-fluoruracil in the treatment of advanced squamous and other selected carcinomas: results of a phase II trial. Cancer 2001, 92(3):642-649.
42. Jhawer M., Mani S., Lefkopoulou M., et al. Phase II study of mitomycin-C, adriamycin, cisplatin (MAP) and bleomycin-CCNU in patients with advanced cancer of the anal canal: an eastern cooperative oncology group study E7282. Invest New Drugs 2006, 24(5):447-454.
43. Harmer MH, editor. TNM classification of Malignant Tumours, 3rd ed. Geneva, Switzerland: UICC; 1978. p. 77-81.
44. UICC TNM-Atlas illustrated guide to the TNM/pTNM-classification of malignant tumours, 2nd ed 1985, Springer-Verlag, Berlin Heidelberg. B. Spiessl, P. Hermanek, O. Scheibe, G. Wagner (Eds.).
45. Chapet O., Gerard J.P., Riche B., et al. Prognostic value of tumour regression evaluated after first course of radiotherapy for anal canal cancer. Int J Radiat Oncol Biol Phys 2005, 63:1316-1324.
46. Gerard J.P., Ayzac L., Hun D., Romestaing P., Coquard R., Ardiet J.M., et al. Treatment of anal canal carcinoma with high dose radiation therapy and concomitant fluorouracil-cisplatinum. Long-term results in 95 patients. Radiother Oncol 1998, 46:249-256.
47. Derniaud-Alexandre E., Touboul E., Tiret E., et al. Results of definitive irradiation in a series of 305 epidermoid carcinomas of the anal canal. Int J Radiat Oncol Biol Phys 2003, 56:1259-1273.
48. Schlienger M., Krzisch C., Pene F., et al. Epidermoid carcinoma of the anal canal: treatment results and prognostic variables in a series of 242 cases. Int J Radiat Oncol Biol Phys 1989, 17:1141-1151.
49. Das P., Bhatia S., Eng C., et al. Predictors and patterns of recurrence after definitive chemoradiation for anal cancer. Int J Radiat Oncol Biol Phys 2007, 68(3):794-800.
50. Nilsson P.J., Svensson C., Goldman S., et al. Epidermoid anal cancer: a review of a population based series of 308 consecutive patients treated according to prospective protocols. Int J Radiat Oncol Biol Phys 2005, 61(1):92-102.
51. Cox J.D., Stetz J., Pajak T.F. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995, 31(5):1341-1346.
52. Peiffert D., Bey P., Pernot M., et al. Conservative treatment by irradiation of epidermoid cancers of the anal canal: prognostic factors of tumoral control and complications. Int J Radiat Oncol Biol Phys 1997, 37(2):313-324.
53. Baxter N.N., Habermann E.B., Tepper J.E., et al. Risk of pelvic fractures in older women following pelvic irradiation. JAMA 2005, 294:2587-2593.
54. Slevin M.L., Plowman P.N., Ryan C.M., et al. Chemoradiotherapy for anal cancer improves quality of life compared to radiotherapy alone. J Clin Oncol 1998, 17. [abstract 266].
55. Deo S.V., Shukla N.K., Raina V., et al. Organ-preserving multimodality management of squamous cell carcinoma of anal canal. Indian J Gastroenterol 2005, 24(5):201-204.
56. Ferrigno R., Nakamura R.A., Dos Santos Novaes P.E., et al. Radiochemotherapy in the conservative treatment of anal carcinoma: retrospective analysis of results and radiation dose effectiveness. Int J Radiat Oncol Biol Phys 2005, 61:1136-1142.
57. Mai S.K., Weitzel G., Hermann B., et al. Long-term outcome after combined radiochemotherapy for anal cancer-retrospective analysis of efficacy, prognostic factors and toxicity. Onkologie 2008, 31(5):251-257.
58. Allal A.S., Sprangers M.A.G., Laurence F., et al. Assessment of long-term quality of life in patients with anal carcinoma treated by radiotherapy with or without chemotherapy. Br J Cancer 1999, 80:1588-1594.
59. Vordermark D., Sailer M., Flentje M., et al. Curative intent radiation therapy in anal carcinomas: quality of life and sphincter function. Radiother Oncol 1999, 52:239-243.
60. Ajani J.A., Winter K.A., Gunderson L.L., et al. Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: the intergroup trial (RTOG 98-11). Cancer 2010, 116(17):4007-4013.
61. Cummings B.J., Keane T.J., O'Sullivan B., et al. Mitomycin in anal canal carcinoma. Oncology 1993, 50(Suppl. 1):63-69.
62. Gerard J.P., Romestaing P., Mahe M., Salerno N. Cancer du Canal Anal: Role de L'association 5-FU-cisplatinum. Lyon Chir 1991, 87:74.
63. Rich T.A., Ajani J.A., Morrison W.H., et al. Chemoradiation therapy for anal cancer: radiation plus continuous infusion of 5-fluorouracil with or without cisplatin. Radiother Oncol 1993, 27:209-215.
64. Hung A., Crane C., Delclos M., et al. Cisplatin-based combined modality therapy for anal carcinoma: a wider therapeutic index. Cancer 2003, 97(5):1195-1202.
65. Goldman S., Norming U., Svensson C., Glimelius B. Transanorectal ultrasonography in the staging of anal epidermoid carcinoma. Int J Colorectal Dis 1991, 6(3):152-157.
66. Brunet R., Sadek H., Vignoud J., et al. Cisplatin (P) and 5-fluorouracil (5FU) for the neoadjuvant treatment of epidermoid anal carcinoma (EACC). J Clin Oncol 1990, 9:104.
67. Ahn J., Cho B., Choi H., et al. Chemoradiation and maintenance chemotherapy with cispaltin and 5-fluorouracil in anal squamous cell carcinoma. J Clin Oncol 2006, 24((18S) part I of II):628s. [Proc. ASCO abstract 14057].
68. Cho B.C., Ahn J.B., Seong J., et al. Chemoradiotherapy with or without consolidation chemotherapy using cisplatin and 5-fluorouracil in anal squamous cell carcinoma: long-term results in 31 patients. BMC Cancer 2008, 15:8.
69. Choi C.H., Lee J.W., Kim T.J., et al. Phase II study of consolidation chemotherapy after concurrent chemoradiation in cervical cancer: preliminary results. Int J Radiat Oncol Biol Phys 2007, 68(3):817-822.
70. Meta-analysis Group. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis from 18 randomized trials. Chemoradiotherapy for cervical cancer meta-analysis grup. J Clin Oncol 2008;26(35):5802-12.
71. Evans T.R.J., Mansi J.L., Glees J.P. Response of metastatic anal carcinoma to single agent carboplatin. Clin Oncol (Royal Coll Radiol) 1993, 5:57-58.
72. Salem P.A., Habboubi N., Anaissie E., et al. Effectiveness of cisplatin in the treatment of anal squamous cell carcinoma. Cancer Treatment Rep 1985, 69:891-893.
73. Khater R., Frenay M., Bourry J., et al. Cisplatin plus 5-fluorouracil in the treatment of metastatic anal squamous cell carcinoma: a report of two cases. Cancer Treat Rep 1986, 70(11):1345-1346.
74. Fisher W.B., Herbst K.D., Sims J.E., et al. Metastatic cloacogenic carcinoma of the anus: sequential responses to adriamycin and cis-dichlorodiammineplatinum(II). Cancer Treat Rep 1978, 62(1):91-97.
75. Ajani J.A., Carrasco C.H., Jackson D.E., et al. Combination of cisplatin plus fluoropyrimidine chemotherapy effective against liver metastases from carcinoma of the anal canal. Am J Med 1989, 87(2):221-224.
76. Tanum G., Tveit K., Karlsen K.O., et al. Chemotherapy and radiation therapy for anal carcinomas. Cancer 1991, 67:2462-2466.
77. Jaiyesimi I.A., Pazdur R. Cisplatin and 5-fluorouracil as salvage therapy for recurrent metastatic carcinoma of the anal canal. Am J Clin Oncol 1993, 16:536-540.
78. Faivre C., Rougier P., Ducreux M., et al. 5-Fluorouracil and cisplatinum combination chemotherapy for metastatic squamous-cell anal cancer. Bull Cancer 1999, 86(10):861-865.
79. Gurfinkel R., Walfisch S. Combined treatment of basaloid anal carcinoma using cisplatin, 5-fluoruracil and resection of hepatic metastasis. Tech Coloproctol 2005, 9:235-236.
80. Hoffman R., Welton M.L., Klencke B., et al. The significance of pretreatment CD4 count on the outcome and treatment tolerance of HIV-positive patients with anal cancer. Int J Radiat Oncol Biol Phys 1999, 44:127-131.
81. Wexler A., Berson A.M., Goldstone S.E., et al. Invasive anal squamous-cell carcinoma in the HIV-positive patient: outcome in the era of highly active antiretroviral therapy. Dis Colon Rectum 2008, 51(1):73-81.
82. Fraunholz I., Rabeneck D., Gerstein J., et al. Concurrent chemoradiotherapy with 5-fluorouracil and mitomycin C for anal carcinoma: are there differences between HIV-positive and HIV-negative patients in the era of highly active antiretroviral therapy?. Radiother Oncol 2010, [Epub ahead of print].
83. Zelen M. The randomization and stratification of patients to clinical trials. J Chronic Dis 1994, 27:365-37584.
84. Borzomati D., Valeri S., Ripetti V., et al. Persisting anal ulcer after radiotherapy for anal cancer: recurrence of disease or late radiation-related complication?. Hepatogastroenterology 2005, 52:780-784.
85. Tanum G., Tveit K.M., Karlsen K.O. Chemoradiotherapy of anal carcinoma: tumour response and acute toxicity. Oncology 1993, 50:14-17.
86. Trautmann T.G., Zuger J.H. Positron emission tomography for pre-treatment staging and posttreatment evaluation in cancer of the anal canal. Mol Imaging Biol 2005, 7:309-313.
87. Schwarz J.K., Siegel B.A., Dehdashti F., et al. Tumor response and survival predicted by post-therapy FDG-PET/CT in anal cancer. Int J Radiat Oncol Biol Phys 2008, 71(1):180-186.
88. Vordermark D. Cause-specific colostomy rates after chemoradiotherapy for anal carcinoma: cancer-related versus treatment related colostomy. J Clin Oncol 2009, 27(18):3065.
89. Glynne-Jones R., Mawdsley S. Anal cancer: the end of the road for neoadjuvant chemoradiotherapy?. J Clin Oncol 2008, 26(22):3667-3669.
90. Gunderson L.L., Winter K.A., Ajani J.A., et al. Long-term update of US GI Intergroup RTOG 98-11 phase III trial for anal carcinoma: comparison of concurrent chemoradiation with 5FU-mitomycin versus 5FU-cisplatin for disease-free and overall survival. J Clin Oncol GI Cancers Symp 2011, 140. [abstract 367].
91. Glynne-Jones R., Northover J.M., Cervantes A. Anal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(Suppl. 5):v87-v92. ESMO Guidelines Working Group.
92. Engstrom P.F., Arnoletti J.P., Benson A.B., et al. NCCN. NCCN clinical practice guidelines in oncology. Anal carcinoma. J Natl Comp Cancer Netw 2010, 8(1):106-120.
93. Schüller J., Cassidy J., Dumont E., et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 2000, 45:291-297.
94. Kachnic L, Winter K, Myerson R, et al. RTOG 0529: A phase II evaluation of dose painted IMRT in combination with 5-fluorouracil and mitomycin C for reduction of acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys 2009;75(3):S5 [Proc ASTRO abstract 10].
95. Kachnic L, winter K, Myerson R, et al. Early efficacy of RTOG-0529: a phase II evaluation of dose painted IMRT in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys 2010;78(3S):s55 [Proc ASTRO abstract 116].
96. Boualga K, Aksil N, Ayad M, et al. Phase I study of Gemcitabine and concomitant radiotherapy in locally advanced carcinoma of the cervix. J Clin Oncol 2005;23:16s [Proc ASCO abstract 5142].
97. Bhatt ML, Matin A, Srivastava M, et al. Evaluation of gemcitabine versus cisplatinum as an adjunct to radiotherapy in locally advanced carcinoma of the uterine cervix. J Clin Oncol 2007;25:18S [Proc ASCO abstract 16012].
98. Lee M.Y., Wu H.G., Kim K., et al. Concurrent radiotherapy with paclitaxel/carboplatin chemotherapy as a definitive treatment for squamous cell carcinoma of the uterine cervix. Gynecol Oncol 2007, 106:95-99.
99. Gaffney D.K., Haslam D., Tsodikov A., et al. Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) negatively affect overall survival in carcinoma of the cervix treated with radiotherapy. Int J Radiat Oncol Biol Phys 2003, 56(4):922-928.
100. Le L.H., Chetty R., Moore M.J. Epidermal growth factor receptor expression in anal canal carcinoma. Am J Clin Pathol 2005, 124:20-23.
101. Alvarez G., Perry A., Tan B.R., et al. Expression of epidermal growth factor receptor in squamous cell carcinomas of the anal canal is independent of gene amplification. Mod Pathol 2006, 19(7):942-949.
102. Zampino M.G., Magni E., Sonzogni A., Renne G. K-ras status in squamous cell anal carcinoma (SCC): it's time for target-oriented treatment?. Cancer Chemother Pharmacol 2009, 65(1):197-199.
103. Evesque L, Etienne-Grimaldi M, Peyrottes I, et al. KRAS and BRAF mutation status in squamous cell carcinoma (SCC) of the anal canal. 2010 Gastrointestinal Cancers Symposium; Cancers of the Colon and Rectum [abstract 326].
104. Paliga AA, Chong G, Onerheim R, et al. KRAS and EGFR gene mutation status in anal canal carcinoma. 2010 Gastrointestinal Cancers Symposium; Cancers of the Colon and Rectum [abstract 352].
105. Phan L.K., Hoff P.M. Evidence of clinical activity for cetuximab combined with irinotecan in a patient with refractory anal canal squamous cell carcinoma: report of a case. Dis Colon Rectum 2007, 50(3):395-398.
106. Lukan N., Ströbel P., Willer A., et al. Cetuximab-based treatment of metastatic anal cancer: correlation of response with KRAS mutational status. Oncology 2009, 77(5):293-299.
107. Pfister D.G., Su Y.B., Kraus D.H., et al. Concurrent cetuximab, cisplatin and concomitant boost radiotherapy for locally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined modality paradigm. J Clin Oncol 2006, 24:1072-1078.
108. González-Cortijo L., Carballo N., González-Martín A., et al. Novel chemotherapy approaches in chemoradiation protocols. Gynecol Oncol 2008, 110(3 Suppl. 2):S45-S48.
109. Huang S.M., Bock J.M., Harari P.M. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 1999, 59:1935-1940.
110. Liang K., Ang K.K., Milas L., et al. The epidermal growth factor receptor mediates radioresistance. Int J Radiat Oncol Biol Phys 2003, 57:246-254.
111. Milas L., Fang F.M., Mason K.A., et al. Importance of maintenance therapy in C225-induced enhancement of tumor control by fractionated radiation. Int J Radiat Oncol Biol Phys 2007, 67:568-572.
112. Andersson U., Johansson D., Benham-Motlagh P., et al. Treatment schedule is of importance when gefitinib is combined with irradiation of glioma and endothelial cells in vitro. Acta Oncol 2007, 46(7):951-960.
113. Pueyo G., Mesia R., Figueras A., et al. Cetuximab may inhibit tumor growth and angiogenesis induced by ionising radiation: a preclinical rationale for maintenance treatment after radiotherapy. Oncologist 2010, 15(9):976-986.